Estimated reading time: 8 minutes
Table of contents
Introduction
Texas Cannabis Reform remains a hot-button issue in 2025 as lawmakers debate the state’s restrictive medical cannabis program, the booming hemp-derived THC market, and potential pathways for broader legalization. Despite overwhelming public support for cannabis reform, legislative action remains uncertain in the Lone Star State.
Texas’ Current Cannabis Landscape
Under the Texas Compassionate Use Program, doctors can prescribe only low-THC cannabis products capped at 1%—a potency closer to hemp than a robust medical cannabis program. This limited framework has spurred an explosion of hemp-derived THC products across the state, creating a multibillion-dollar market. In response, Lt. Gov. Dan Patrick is pushing Senate Bill 3, a controversial measure aimed at banning THC sales by unlicensed retailers.
Public Opinion and Legislative Momentum
While Patrick’s proposed crackdown on unregulated THC sales has garnered 55% support, Texans overwhelmingly favor broader cannabis reform. A February 2024 University of Houston Hobby School of Public Affairs report found that:
- 79% of Texans support medical cannabis legalization.
- 62% support adult-use legalization.
With the 2025 legislative session underway—Texas lawmakers meet only in odd-numbered years—there is a limited window for elected officials to align policy with voter sentiment.
Legislative Efforts in 2025
Since the Compassionate Use Program’s inception in 2015, Texas lawmakers have incrementally expanded it, raising the THC cap and increasing qualifying conditions. However, the current framework remains one of the most restrictive in the nation.
This session, several cannabis-related bills have been introduced, including:
- Adult-Use Legalization: Rep. Jessica Gonzalez (D-Dallas) filed a bill to legalize adult-use cannabis for those 21 and older.
- Medical Cannabis Expansion: Three notable bills aim to expand access:
- Senate Bill 170 – Filed by Sen. José Menéndez (D-San Antonio).
- Senate Bill 259 – Filed by Sen. Carol Alvarado (D-Houston).
- House Bill 1504 – Filed by Rep. Ron Reynolds (D-Fort Bend).
In total, more than 25 cannabis- and hemp-related bills have been introduced this session, highlighting the growing urgency of reform discussions.
Conclusion
Texas Cannabis Reform is at a crossroads in 2025. While restrictive policies persist, strong public support and legislative proposals signal potential progress. Whether the state will embrace meaningful reform or continue its incremental approach remains to be seen, but the conversation is far from over.
Learn more about our full-service cannabis and hemp consulting services tailored to Texas’s unique market needs.
Texas Cannabis Reform 2025 FAQs
The Texas Compassionate-Use Act established requirements for the licensing and registration of dispensaries who provide low-THC cannabis to qualified patients. This chapter of Texas law allows qualified physicians to prescribe low-THC cannabis to certain qualifying patients.
Once the medical cannabis doctor has confirmed your eligibility, they will customize an individual treatment plan and register you in the Compassionate Use Registry of Texas (CURT). In contrast with other states, in Texas, there is no medical marijuana card.
As of April 2024, possession of any amount of a THC edible is a felony. If the amount in your possession is less than a gram, it’s a state jail felony that carries from 180 days to two years in jail, and possession of more than a gram carries a prison sentence.
Recreational use of marijuana, including marijuana-derived THC gummies, remains highly illegal in Texas. They treat it as a schedule I narcotic, in accordance with federal law. Possession of even small amounts of marijuana can lead to legal consequences, including fines, jail time, or both.
Texas passed House Bill 1325 in 2019, which allowed for the commercialization of hemp at the state level. The law, which was meant to promote agriculture, also made it possible for Texas businesses to sell low-level THC products.
No, Delta-9 THC is not legal for recreational use in Texas. Under Texas law, Delta-9 THC is classified as a controlled substance, making it illegal unless it’s derived from hemp and contains less than 0.3% THC by dry weight, in line with the federal 2018 Farm Bill.
In 2015, Texas passed the Compassionate-Use Act. This Act allowed the first legal use of low-THC cannabis products in the state for patients with intractable epilepsy. It was expanded in 2019 and 2021 to include other conditions.
The following are the current qualifying conditions for medical marijuana in Texas: Autism, Cancer, Chronic Pain, Dementia, Huntington’s Disease, Multiple Sclerosis, PTSD, Reducing Inflammation, Sleep Issues, Spasticity, Stress, and Anxiety.
Texas’s Compassionate Use Program (CUP) allows certain physicians to prescribe low tetrahydrocannabinols (THC) cannabis for medical purposes. Low-THC comes from the plant Cannabis Sativa L.
No, Delta-9 THC is not legal for recreational use in Texas. Under Texas law, Delta-9 THC is classified as a controlled substance, making it illegal unless it’s derived from hemp and contains less than 0.3% THC by dry weight, in line with the federal 2018 Farm Bill.
Additional Resources
Free eBooks For Cannabis Business Success
Latest Articles
- The Fiduciary Mandate: Why an Owner’s Rep is the Key to 2026 Cannabis Retail Success
In the cannabis retail landscape of 2026, the era of “opening at any cost” has ended. As capital markets remain disciplined and consumer margins tighten, the difference between a profitable dispensary and a “zombie project” is determined during the buildout phase. - Open a Cannabis Consumption Lounge in New Jersey: 2026 Guide to Compliance and Success
As of April 2026, the New Jersey cannabis market has matured into a sophisticated $4 billion powerhouse. The initial “novelty” phase has passed, and the industry is now defined by “Hospitality 2.0,” where consumption areas are becoming social anchors for local tourism in hubs like Atlantic City, Newark, and Jersey City. - New York Cannabis Lounge License: Expert Guide to Compliance and Success
The New York cannabis industry has transitioned from a volatile implementation phase into a “Pharma-Grade” era of structural maturity. As of April 2026, the state has reached a monumental economic milestone, with total reported retail sales officially surpassing $3,000,000,000. For entrepreneurs, the current frontier is the “social hospitality” sector, which is defined by high-stakes technical compliance and rigorous municipal negotiation. - The 2026 New York Execution Gap: Scaling Your Cannabis Business
The trajectory of the New York cannabis industry has transitioned from a period of experimental regulation to one of massive commercial consolidation and operational intensity. As of April 15, 2026, the state has officially matured into its role as the second-largest cannabis market in the United States, trailing only California in total economic activity and consumer demand. The primary indicator of this success is the milestone reached in early 2026, where total reported retail sales since the inception of the legal program surpassed $2.97 billion. - Regulatory Maturity and Market Dynamics: A Comprehensive Analysis of the New Jersey Cannabis Industry
The legal landscape of cannabis in New Jersey has transitioned from a period of rapid legislative enactment into an era of complex regulatory maturity and secondary market correction. Since the foundational passage of the New Jersey Cannabis Regulatory, Enforcement Assistance, and Marketplace Modernization Act (CREAMMA) in early 2021, the state has systematically dismantled the architecture of prohibition while constructing a highly regulated, billion-dollar industry. - Nebraska Medical Cannabis Market Strategic Report: Navigating the Regulatory Landscape and Licensing Framework 2026
The Nebraska medical cannabis industry has undergone a radical transformation from its nascent beginnings in the 2024 general election to the highly structured, albeit restrictive, regulatory environment of April 2026. This period has been characterized by intense legislative maneuvering, high-stakes licensing competitions, and a fundamental shift in the state’s administrative approach to controlled substances.